ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate, BPZE1, is the most advanced next generation pertussis vaccine, having completed four Phase 2 clinical trials. ILiAD Biotechnologies, Inc. is a registered Delaware company founded in 2012.
Founded in 2020, BioLyo Technologies, BV is a wholly-owned ILiAD subsidiary based in Ghent, Belgium. BioLyo is a Contract Development Manufacturing Organization (CDMO) focused on process and analytical development for Live Bacterial Products. Click here to learn more.
